Background Ipilimumab (Ip) is an option in Metastatic Melanoma (MM) patients (pt) in case of disease progression after antiPD1 (AP) treatment and BRAF+MEK inhibitors (BMi) administration (for BRAF mutated melanoma). Clinical trial are evaluating potential Ip-based combinations in 2nd/3rd line setting. Many studies underline the role of some parameters (as LDH, ECOG PS, Neutrophile/Leucocyte ratio) […]

Background: Among patients (pts) with stage IV melanoma, the presence of brain metastases (BM) is associated with poor prognosis. Namely, median overall survival (OS) is about 4-6 months. Aim of the present study is to evaluate whether BM detection pattern (symptomatic vs radiological) may affect clinical outcome. Patients and Methods: The retrospective series included 150 […]

Background: High BMI is associated with better survival in metastatic melanoma patients (MM pts), while the prognostic value of sarcopenia is unknown in these pts. The aim of this study was to examine the prognostic impact of body-mass index (BMI), baseline sarcopenia and loss of skeletal muscle mass (LSMM) on overall survival (OS) in MM […]

Background Checkpoint inhibitors, immunomodulatory antibodies that are used to enhance the immune system, have substantially improved the prognosis for patients with advanced malignancy. The management of toxicities due to mmunotherapy is an emergent topic. We explored individual medical experience and practice. Methods Italian medical doctor members of the Italian Melanoma Intergroup were invited to participate […]

Background Despite recent advances in treatment, at present malignant melanoma remains a devastating disease. Preclinical data suggest that immunotherapy may synergize the “abscopal” effect of radiotherapy and to generate “abscopal” responses outside the radiation field. The “abscopal” phenomenon remains relatively unexplored and shows that radiation may induce a regression of tumor cells outside the field […]

Background Melanoma that metastasizes to the brain has a poor prognosis, and accounts for up to 54% of melanoma deaths. Clinical data show that treatment with BRAF-targeted agents induces responses in RAFV600-mutant MBM. Duration of response in the brain is shorter than that observed with extracranial disease. The BRAF/MEK-targeted combination encorafenib + binimetinib demonstrated favorable […]

Background Over 60% of patients (pts) with stage IV melanoma may develop brain metastases, resulting in a significantly increased morbidity and poor overall prognosis. Clinical data for melanoma brain metastases (MBM) treatments are limited, as controlled studies often exclude pts with untreated brain metastases. Methods We conducted a multicenter, retrospective case series investigation with consecutive […]

Background Ipilimumab (Ip) is an option in Metastatic Melanoma (MM) patients (pt) in case of disease progression after antiPD1 (AP) treatment and BRAF+MEK inhibitors (BMi) administration (for BRAF mutated melanoma). Clinical trial are evaluating potential Ip-based combinations in 2nd/3rd line setting. Many studies underline the role of some parameters (as LDH, ECOG PS, Neutrophile/Leucocyte ratio) […]

Background Patients (pts) with melanoma brain metastases (BM) have a historically poor prognosis, with a reported median overall survival (mOS) of 4-6 months. Aim of this study is to evaluate predictive factors of survival in pts with melanoma BM. Secondly, a multivariate model was used to define groups with distinct prognosis. Methods Consecutive pts with […]